This finding suggests that the mechanism of action of DNMT3A mutations in T-ALL may be different to AML, possibly due to the necessity of contributing genetic or epigenetic aberrations in T-ALL compared to AML [27]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.